@article{bousiges_cerebrospinal_2018-1,
	title = {Cerebrospinal fluid {Alzheimer} biomarkers can be useful for discriminating dementia with {Lewy} bodies from {Alzheimer}'s disease at the prodromal stage},
	volume = {89},
	issn = {1468-330X},
	doi = {10.1136/jnnp-2017-316385},
	abstract = {BACKGROUND: Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.
METHODS: A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients.
RESULTS: In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P{\textless}0.05 CS{\textgreater}pro-DLB; P{\textless}0.001 CS{\textgreater}DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P{\textless}0.001 DLB groups{\textless}pro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 levels were unaltered in patients with DLB (pro-DLB and DLB-d).
CONCLUSIONS: Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181 were the best biomarkers to discriminate between AD and DLB, whatever the stage of disease.},
	language = {eng},
	number = {5},
	journal = {Journal of Neurology, Neurosurgery, and Psychiatry},
	author = {Bousiges, Olivier and Bombois, Stephanie and Schraen, Susanna and Wallon, David and Quillard, Muriel Muraine and Gabelle, Audrey and Lehmann, Sylvain and Paquet, Claire and Amar-Bouaziz, Elodie and Magnin, Eloi and Miguet-Alfonsi, Carole and Delbeuck, Xavier and Lavaux, Thomas and Anthony, Pierre and Philippi, Nathalie and Blanc, Frederic and {ePLM network and collaborators}},
	month = may,
	year = {2018},
	pmid = {29321140},
	keywords = {Aged, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Case-Control Studies, Diagnosis, Differential, Female, Humans, Lewy Body Disease, Male, Middle Aged, Peptide Fragments, Prodromal Symptoms, Retrospective Studies, tau Proteins},
	pages = {467--475},
}

{"_id":"2pAsttrt2v9gma9HD","bibbaseid":"bousiges-bombois-schraen-wallon-quillard-gabelle-lehmann-paquet-etal-cerebrospinalfluidalzheimerbiomarkerscanbeusefulfordiscriminatingdementiawithlewybodiesfromalzheimersdiseaseattheprodromalstage-2018","authorIDs":[],"author_short":["Bousiges, O.","Bombois, S.","Schraen, S.","Wallon, D.","Quillard, M. M.","Gabelle, A.","Lehmann, S.","Paquet, C.","Amar-Bouaziz, E.","Magnin, E.","Miguet-Alfonsi, C.","Delbeuck, X.","Lavaux, T.","Anthony, P.","Philippi, N.","Blanc, F.","ePLM network","collaborators"],"bibdata":{"bibtype":"article","type":"article","title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage","volume":"89","issn":"1468-330X","doi":"10.1136/jnnp-2017-316385","abstract":"BACKGROUND: Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. METHODS: A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. RESULTS: In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P\\textless0.05 CS\\textgreaterpro-DLB; P\\textless0.001 CS\\textgreaterDLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P\\textless0.001 DLB groups\\textlesspro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 levels were unaltered in patients with DLB (pro-DLB and DLB-d). CONCLUSIONS: Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181 were the best biomarkers to discriminate between AD and DLB, whatever the stage of disease.","language":"eng","number":"5","journal":"Journal of Neurology, Neurosurgery, and Psychiatry","author":[{"propositions":[],"lastnames":["Bousiges"],"firstnames":["Olivier"],"suffixes":[]},{"propositions":[],"lastnames":["Bombois"],"firstnames":["Stephanie"],"suffixes":[]},{"propositions":[],"lastnames":["Schraen"],"firstnames":["Susanna"],"suffixes":[]},{"propositions":[],"lastnames":["Wallon"],"firstnames":["David"],"suffixes":[]},{"propositions":[],"lastnames":["Quillard"],"firstnames":["Muriel","Muraine"],"suffixes":[]},{"propositions":[],"lastnames":["Gabelle"],"firstnames":["Audrey"],"suffixes":[]},{"propositions":[],"lastnames":["Lehmann"],"firstnames":["Sylvain"],"suffixes":[]},{"propositions":[],"lastnames":["Paquet"],"firstnames":["Claire"],"suffixes":[]},{"propositions":[],"lastnames":["Amar-Bouaziz"],"firstnames":["Elodie"],"suffixes":[]},{"propositions":[],"lastnames":["Magnin"],"firstnames":["Eloi"],"suffixes":[]},{"propositions":[],"lastnames":["Miguet-Alfonsi"],"firstnames":["Carole"],"suffixes":[]},{"propositions":[],"lastnames":["Delbeuck"],"firstnames":["Xavier"],"suffixes":[]},{"propositions":[],"lastnames":["Lavaux"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Anthony"],"firstnames":["Pierre"],"suffixes":[]},{"propositions":[],"lastnames":["Philippi"],"firstnames":["Nathalie"],"suffixes":[]},{"propositions":[],"lastnames":["Blanc"],"firstnames":["Frederic"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["ePLM network"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["collaborators"],"suffixes":[]}],"month":"May","year":"2018","pmid":"29321140","keywords":"Aged, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Case-Control Studies, Diagnosis, Differential, Female, Humans, Lewy Body Disease, Male, Middle Aged, Peptide Fragments, Prodromal Symptoms, Retrospective Studies, tau Proteins","pages":"467–475","bibtex":"@article{bousiges_cerebrospinal_2018-1,\n\ttitle = {Cerebrospinal fluid {Alzheimer} biomarkers can be useful for discriminating dementia with {Lewy} bodies from {Alzheimer}'s disease at the prodromal stage},\n\tvolume = {89},\n\tissn = {1468-330X},\n\tdoi = {10.1136/jnnp-2017-316385},\n\tabstract = {BACKGROUND: Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau181, total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage.\nMETHODS: A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients.\nRESULTS: In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P{\\textless}0.05 CS{\\textgreater}pro-DLB; P{\\textless}0.001 CS{\\textgreater}DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P{\\textless}0.001 DLB groups{\\textless}pro-AD). The Aβ42/Aβ40 ratio in patients with pro-DLB remained close to that of CS. t-Tau and phospho-Tau181 levels were unaltered in patients with DLB (pro-DLB and DLB-d).\nCONCLUSIONS: Reduced levels of CSF Aβ42 were found in patients with DLB but rather at a later stage, reaching those of patients with AD, in whom Aβ42 levels were decreased even at the prodromal stage. At the prodromal stage of DLB, the majority of patients presented a normal CSF profile. CSF t-Tau and phospho-Tau181 were the best biomarkers to discriminate between AD and DLB, whatever the stage of disease.},\n\tlanguage = {eng},\n\tnumber = {5},\n\tjournal = {Journal of Neurology, Neurosurgery, and Psychiatry},\n\tauthor = {Bousiges, Olivier and Bombois, Stephanie and Schraen, Susanna and Wallon, David and Quillard, Muriel Muraine and Gabelle, Audrey and Lehmann, Sylvain and Paquet, Claire and Amar-Bouaziz, Elodie and Magnin, Eloi and Miguet-Alfonsi, Carole and Delbeuck, Xavier and Lavaux, Thomas and Anthony, Pierre and Philippi, Nathalie and Blanc, Frederic and {ePLM network and collaborators}},\n\tmonth = may,\n\tyear = {2018},\n\tpmid = {29321140},\n\tkeywords = {Aged, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Case-Control Studies, Diagnosis, Differential, Female, Humans, Lewy Body Disease, Male, Middle Aged, Peptide Fragments, Prodromal Symptoms, Retrospective Studies, tau Proteins},\n\tpages = {467--475},\n}\n\n","author_short":["Bousiges, O.","Bombois, S.","Schraen, S.","Wallon, D.","Quillard, M. M.","Gabelle, A.","Lehmann, S.","Paquet, C.","Amar-Bouaziz, E.","Magnin, E.","Miguet-Alfonsi, C.","Delbeuck, X.","Lavaux, T.","Anthony, P.","Philippi, N.","Blanc, F.","ePLM network","collaborators"],"key":"bousiges_cerebrospinal_2018-1","id":"bousiges_cerebrospinal_2018-1","bibbaseid":"bousiges-bombois-schraen-wallon-quillard-gabelle-lehmann-paquet-etal-cerebrospinalfluidalzheimerbiomarkerscanbeusefulfordiscriminatingdementiawithlewybodiesfromalzheimersdiseaseattheprodromalstage-2018","role":"author","urls":{},"keyword":["Aged","Alzheimer Disease","Amyloid beta-Peptides","Biomarkers","Case-Control Studies","Diagnosis","Differential","Female","Humans","Lewy Body Disease","Male","Middle Aged","Peptide Fragments","Prodromal Symptoms","Retrospective Studies","tau Proteins"],"downloads":0},"bibtype":"article","biburl":"https://api.zotero.org/users/1776321/collections/F6GQXILV/items?key=oJXO0XMJPUSYebC0WkzhO6dj&format=bibtex&limit=100","creationDate":"2021-02-10T14:03:34.473Z","downloads":0,"keywords":["aged","alzheimer disease","amyloid beta-peptides","biomarkers","case-control studies","diagnosis","differential","female","humans","lewy body disease","male","middle aged","peptide fragments","prodromal symptoms","retrospective studies","tau proteins"],"search_terms":["cerebrospinal","fluid","alzheimer","biomarkers","useful","discriminating","dementia","lewy","bodies","alzheimer","disease","prodromal","stage","bousiges","bombois","schraen","wallon","quillard","gabelle","lehmann","paquet","amar-bouaziz","magnin","miguet-alfonsi","delbeuck","lavaux","anthony","philippi","blanc","eplm network","collaborators"],"title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage","year":2018,"dataSources":["PfLq66s9axHfjLkSp"]}